Freiburg im Breisgau, Germany (Scicasts) — Dr. Florian Weinberg, from Prof. Dr. Tilman Brummer's research group at the Institute of Molecular Medicine and Cell Research (IMMZ) of the University of Freiburg, joined forces with scientists from the Departments of Clinical Pathology and Medicine I of the University Medical Centre Freiburg and the Kinghorn Cancer Centre/Garvan Insitute in Australia in an international team that has identified a new target for cancer therapy. The researchers discovered that the enzyme RIOK1 collaborates with the RAS protein, which is often mutated in tumours and therefore promotes tumour growth and the development of metastases. These secondary tumours are spread by the primary tumour, if it is not removed in time, and are the cause of death in most cancer patients. The researchers believe it may be possible to use so-called inhibitors to block the enzymatic activity of RIOK1, thereby slowing down the disease's progression. The team has recently published its findings in the translational journal EBioMedicine.

Cancer diseases are characterized by gene mutations that cause the uncontrolled growth of the body's own cells. This, in turn, results in the development of tumours. Most treatments combine surgery to remove the tumour with chemotherapy or radiation therapy, both of which are used to inhibit the fast growth of cells. Specific inhibitors can also be used as an additional or alternative therapy. These drugs inhibit the activity of the harmful proteins and enzymes produced by the mutated genes in tumours. However, there are currently only very few ways to specifically treat RAS-driven tumours. Because roughly 30 percent of all cancer patients carry a Ras mutation in their tumours, there is a very strong need to find new ways to target RAS.

The team of scientists studied the growth behaviour of human RAS-mutated lung-, breast-, and colorectal cancer cells in cell culture and animal models. In each case, they were able to genetically modify the cells, so that they were no longer able to produce RIOK1, a method that mimics the effects of a still to be developed RIOK1 inhibitor. By this approach, the authors were able to reduce the growth and aggressiveness of the cancer cells. Especially in the animal models, the researchers observed that the modified cells were no longer able to form metastases. RIOK1 belongs to the enzyme family of protein kinases for which inhibitors are already successfully used in cancer therapy. Therefore, the scientists believe that similar substances inhibiting the enzymatic activity of RIOK1 could be developed in the near future. In addition, RIOK1 could be used to predict the progression of lung and breast cancer more accurately, as the researchers observed an increased production of RIOK1 in the tumour tissue of patients who had a poorer prognosis.

The researchers stated that more studies are needed to confirm RIOK1 as a target for cancer therapy, however. It would be important, for example, to understand the exact mechanism through which the enzyme supports cancer growth and metastasis. It is also essential that inhibitors be tested first on model organisms before the drugs can be tested in clinical studies. The researchers' initial studies on roundworms and human cells have demonstrated that healthy body cells are either only partially affected or not affected at all by the loss of RIOK1, because they do not depend on the enzyme. This would mean that, at the same time, cancer cells would be inhibited from growing and from spreading new tumours.

Article adapted from a University of Freiburg news release.

Publication: The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior. Florian Weinberg et al. EBioMedicine (2017): Click here to view.